We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Kevin C. Clayton

Washington, D.C.

Kevin C. Clayton

Kevin Clayton is an experienced advisor who provides practical and cost-effective advice to clients in corporate and commercial matters. Kevin regularly advises clients in mergers and acquisitions, complex contracting and corporate governance matters, and equity and debt financings, and particularly focuses on representation of private equity and venture capital funds and start-up and venture-backed companies in acquisition, financing, and commercial transactions.

Beyond his substantial knowledge of mergers and acquisitions and financing transactions, Kevin also has years of experience managing a wide array of commercial matters and complex contracting arrangements, such as license, supply, distribution, collaboration, manufacturing, service, employment, and consulting agreements. He is also very experienced handling distressed asset transactions, joint ventures, strategic alliances, and other general corporate matters.

In addition to providing counsel to publicly traded and later-stage privately held companies, Kevin represents emerging and early-stage companies on formation, structuring, financing, and commercial matters.

Kevin represents clients in various industry sectors, but has particular experience with matters in the life sciences and technology sectors.

Representative experience

Represented New Enterprise Associates as lead investor in more than a dozen venture capital financing transactions over the past several years.

Represented OptiNose, Inc. in its 2015 Series C-1 financing, prior financings and general corporate matters.

Represented Fred Hutchinson Cancer Research Center in Juno Therapeutics, Inc.'s US$176m Series A financing, US$134m Series B financing and related matters.

Represented PhishMe. Inc. in its Series A and B financings, general corporate matters and transaction with Malcovery Security, LLC.

Represented New York University in connection with Spin Transfer Technologies, Inc.'s US$70m financing and other similar transactions.

Represented publicly traded biotechnology company in several acquisitions and divestitures and numerous strategic venture investments.

Represented a luxury vacation club in a variety of equity financings, mortgage-backed debt financings, and acquisitions.

Represented Dental Care Alliance, LLC in its 2015 sale to Harvest Partners, LP.

Education and admissions


  • J.D., University of Virginia School of Law, 1998
  • B.A., University of Virginia, 1992

Bar admissions and qualifications

  • District of Columbia
  • Virginia
Loading data